Erste Asset Management Gmb H Kodiak Sciences Inc. Transaction History

Erste Asset Management Gmb H

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 26, 2024	BUY	$7.57 - $12.5 $85,541 - $141,250	11,300 New	11,300 $85.9 Million
Q2 2022 Nov 26, 2024	BUY	$5.04 - $9.48 $56,952 - $107,124	11,300 New	11,300 $89.5 Million
Q1 2022 Nov 22, 2024	SELL	$7.09 - $89.45 $17,016 - $214,680	-2,400 Reduced 17.52%	11,300 $87.3 Million
Q4 2021 Nov 22, 2024	BUY	$80.85 - $128.49 $1.11 Million - $1.76 Million	13,700 New	13,700 $1.21 Billion
Q4 2020 Nov 22, 2024	BUY	$60.78 - $154.03 $832,686 - $2.11 Million	13,700 New	13,700 $2 Billion

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $455M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Erste Asset Management Gmb H with notifications on news.